The Effect of Positive End Expiratory Pressure on Central Venous Pressure Among Patients With Different Lung Compliance
1 other identifier
interventional
30
1 country
1
Brief Summary
To observe the effect of PEEP on CVP among patients with different respiratory compliance
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable sepsis
Started Nov 2017
Shorter than P25 for not_applicable sepsis
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 8, 2017
CompletedStudy Start
First participant enrolled
November 13, 2017
CompletedFirst Posted
Study publicly available on registry
November 14, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 30, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2017
CompletedNovember 14, 2017
November 1, 2017
2 months
November 8, 2017
November 13, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
CVP
Measure the central venous pressure of the three level PEEPs of 5,10 and 15cmH2O.
half an hour
Study Arms (2)
high response group
EXPERIMENTALpatients undergo 5,10 and 15cmH2O positive end expiratory pressure ,the change of central venous pressure is more than 2.5cmH2O
low response group
PLACEBO COMPARATORthe change of CVP is less than 2.5cmH2O
Interventions
every patients undergo 5,10 and 15cmH2O positive end expiratory pressure,and observe the central venous pressure of the mentioned points
Eligibility Criteria
You may qualify if:
- \. Patients with mechanical ventilation and inserted central venous line
You may not qualify if:
- The age is less than 18 years old or more than 80 years old；
- Pregnant and lying-in woman；
- Patients undergoing fluid resuscitation and the speed is more than 200ml/h；
- Patients with norepinephrine dose are greater than 15 micro per minute；
- Patients with pericarditis、pulmonary heart disease、right heart failure、atrial fibrillation；
- Patients with COPD(endogenous PEEP is more than 2cmH2O)、tension pneumonthorax、acute episode asthma
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Jingyuan,Xulead
Study Sites (1)
Zhongda Hospital
Nanjing, Jiangsu, 210000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY CHAIR
yi yang, doctor
Zhongda Hospital
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- SUPPORTIVE CARE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Attending doctor
Study Record Dates
First Submitted
November 8, 2017
First Posted
November 14, 2017
Study Start
November 13, 2017
Primary Completion
December 30, 2017
Study Completion
December 30, 2017
Last Updated
November 14, 2017
Record last verified: 2017-11
Data Sharing
- IPD Sharing
- Will not share